Use of novel metalloporphyrins as imageable tumor-targeting agents for radiation therapy
AssigneeBrookhaven Science Associates, LLC
InventorsMichiko Miura, Daniel N. Slatkin
Life of this patent
Estimating the term…
Abstract
The present invention covers halogenated derivatives of boronated phorphyrins containing multiple carborane cages having the formula 1 which selectively accumulate in neoplastic tissue within the irradiation volume and thus can be used in cancer therapies including, but not limited to, boron neutron-capture therapy and photodynamic therapy. The present invention also covers methods for using these halogenated derivatives of boronated porphyrins in tumor imaging and cancer treatment.
Claims16
A method of tumor imaging using single-photon-emission tomography (SPECT) wherein the tumor imaging agent administered to the subject is a pharmaceutically acceptable composition containing a compound of the formula
- 4
- wherein M is a SPECT imageable radiometal with or without another carrier metal, R is selected from the group consisting of hydrogen, a halogen, a halogen isotope, or a nitro group, with at least one R being a halogen, a halogen isotope or a nitro group, and Y is selected from the group consisting of ortho, meta, or para O(CH2)nC2HB9H10 or O(CH2)nC2HB10H10 wherein, 0≦n≦20 and C2HB9H10 is nido ortho, meta- or para-carborane and C2HB10H10 is ortho-carborane, meta-carborane or para-carborane.
A method of tumor imaging using positron emission tomography (PET) wherein the tumor imaging agent administered to the subject is a pharmaceutically acceptable composition containing a compound of the formula
- 5
- wherein M is a PET imageable radiometal with or without another carrier metal, R is selected from the group consisting of hydrogen, a halogen, a halogen isotope, or a nitro group, with at least one R being a halogen, a halogen isotope or a nitro group, and Y is selected from the group consisting of ortho, meta, or para O(CH2)nC2HB9H10 or O(CH2)nC2HB10H10 wherein, 0≦n≦20 and C2HB9H10 is nido ortho, meta- or para-carborane and C2HB10 H10 is ortho-carborane, meta-carborane or para-carborane.
A method of bimodal cancer treatment wherein the tumor targeting agent administered to the subject is a pharmaceutically acceptable composition containing a compound of the formula
- 6
- wherein M is a single-photon-emission tomography imageable radiometal or a paramagnetic metal, R is selected from the group consisting of hydrogen, a halogen, a halogen isotope, or a nitro group, with at least one R being a halogen, a halogen isotope or a nitro group, and Y is selected from the group consisting of ortho, meta, or para O(CH2)nC2HB9H10 or O(CH2)nC2HB10H10 wherein, 0≦n≦20 and C2 HB9H10 is nido ortho, meta- or para-carborane and C2HB10H10 is ortho-carborane, meta-carborane or para-carborane.
Dependencies are inferred from the claim text.